Literature DB >> 17462577

LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

Yik Khuan Ho1, Paola Bargagna-Mohan, Marie Wehenkel, Royce Mohan, Kyung-Bo Kim.   

Abstract

The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. However, its other pathophysiological functions are still not very well understood. This can be attributed mainly to a lack of appropriate molecular probes that can selectively modulate the immunoproteasome catalytic subunits. Herein, we report the development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome. We show that these compounds irreversibly modify the LMP2 subunit with high specificity. Importantly, LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462577      PMCID: PMC5541682          DOI: 10.1016/j.chembiol.2007.03.008

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  49 in total

1.  An algorithm for the prediction of proteasomal cleavages.

Authors:  C Kuttler; A K Nussbaum; T P Dick; H G Rammensee; H Schild; K P Hadeler
Journal:  J Mol Biol       Date:  2000-05-05       Impact factor: 5.469

Review 2.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  SCF and Cullin/Ring H2-based ubiquitin ligases.

Authors:  R J Deshaies
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

4.  Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Authors:  J Myung; K B Kim; K Lindsten; N P Dantuma; C M Crews
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

5.  Catalytic properties of 26 S and 20 S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities.

Authors:  J Reidlinger; A M Pike; P J Savory; R Z Murray; A J Rivett
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

6.  Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome".

Authors:  C Cardozo; R A Kohanski
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

7.  Differences in catalytic activities and subunit pattern of multicatalytic proteinase complexes (proteasomes) isolated from bovine pituitary, lung, and liver. Changes in LMP7 and the component necessary for expression of the chymotrypsin-like activity.

Authors:  C Cardozo; A M Eleuteri; M Orlowski
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

8.  Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Masaharu Akiyama; Nicholas Mitsiades; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

9.  Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex.

Authors:  K Früh; M Gossen; K Wang; H Bujard; P A Peterson; Y Yang
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

10.  Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation.

Authors:  T Korff; H G Augustin
Journal:  J Cell Biol       Date:  1998-11-30       Impact factor: 10.539

View more
  46 in total

1.  Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules.

Authors:  Danielle de Verteuil; Tara L Muratore-Schroeder; Diana P Granados; Marie-Hélène Fortier; Marie-Pierre Hardy; Alexandre Bramoullé; Etienne Caron; Krystel Vincent; Sylvie Mader; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  Mol Cell Proteomics       Date:  2010-05-19       Impact factor: 5.911

Review 2.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway.

Authors:  Eun Ryoung Jang; Na-Ra Lee; Songhee Han; Ying Wu; Lalit Kumar Sharma; Kimberly Cornish Carmony; James Marks; Do-Min Lee; Jung-Ok Ban; Marie Wehenkel; Jin Tae Hong; Kyung Bo Kim; Wooin Lee
Journal:  Mol Biosyst       Date:  2012-06-22

Review 4.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

5.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.

Authors:  Matthew Britton; Marcella M Lucas; Sondra L Downey; Michael Screen; Alexandre A Pletnev; Martijn Verdoes; Robert A Tokhunts; Omar Amir; Ayrton L Goddard; Philip M Pelphrey; Dennis L Wright; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2009-12-24

Review 6.  Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.

Authors:  Kyung Bo Kim; Craig M Crews
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

7.  Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.

Authors:  Lin Ao; Ying Wu; Donghern Kim; Eun Ryoung Jang; Kyunghwa Kim; Do-Min Lee; Kyung Bo Kim; Wooin Lee
Journal:  Mol Pharm       Date:  2012-07-13       Impact factor: 4.939

8.  Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Authors:  Henry W B Johnson; Janet L Anderl; Erin K Bradley; John Bui; Jeffrey Jones; Shirin Arastu-Kapur; Lisa M Kelly; Eric Lowe; David C Moebius; Tony Muchamuel; Christopher Kirk; Zhengping Wang; Dustin McMinn
Journal:  ACS Med Chem Lett       Date:  2017-03-09       Impact factor: 4.345

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

Review 10.  Proteasome regulators: activators and inhibitors.

Authors:  Li Huang; Chin Ho Chen
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.